Jasper Therapeutics (JSPR)

• Market cap: $39.5M
• 1 day: -5.08%
• 5 days: -12.59%
• 1 month: -14.74%
• 3 months: -56.37%
• 6 months: -54.92%
• Year to date: -88.48%
• 1 year: -88.68%
• 5 years: -97.56%
• 10 years: -97.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Employees: 64

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]

24% more capital invested

Capital invested by funds: $56M [Q1] → $69.5M (+$13.4M) [Q2]

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

3.47% less ownership

Funds ownership: 86.78% [Q1] → 83.31% (-3.47%) [Q2]

4% less funds holding

Funds holding: 67 [Q1] → 64 (-3) [Q2]

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

23% less call options, than puts

Call options by funds: $232K | Put options by funds: $302K

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4
• Avg. target: $16.83
• High target: $25

6 analyst ratings

• positive: 5 83%
• neutral: 1 17%
• negative: 0 0%

UBS Trung Huynh	$25	Buy Maintained	15 Aug 2025
BMO Capital Kostas Biliouris	$4	Market Perform Downgraded	8 Jul 2025
JMP Securities Silvan Tuerkcan	$12	Market Outperform Maintained	8 Jul 2025
Evercore ISI Group Gavin Clark-Gartner	$20	Outperform Maintained	8 Jul 2025
HC Wainwright & Co. Emily Bodnar	$20	Buy Maintained	7 Jul 2025